Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04351334 · ClinicalTrials.gov registry record
Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC) Post-alectinib Treatment Patterns
A clinical trial of Non-Small-Cell Lung Carcinoma, sponsored by Pfizer.
- Completed
- Registry status
- 161
- Enrollment target
- 1
- Study location
NCT04351334 is a study of Non-Small-Cell Lung Carcinoma that has completed, run by Pfizer. The registered enrollment target is 161 participants, below the 230-participant average among 30 other Non-Small-Cell Lung Carcinoma trials with a reported enrollment target (30% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04351334, a study of Non-Small-Cell Lung Carcinoma, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 161 participants
- Enrollment target
- 1
- Study location
Study Summary
This study aims to understand patient profiles, treatment patterns, and clinical outcomes among ALK-positive NSCLC patients treated with alectinib, and post-alectinib treatment patterns and outcomes.
Conditions Studied
Interventions
- DRUG Alectinib
Study Locations (1)
New York
- Pfizer Inc - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 161 participants |
| Start Date | 2020-03-01 |
| Est. Completion | 2022-11-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04351334
The ClinicalTrials.gov registry entry for NCT04351334 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 161 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 230-participant average among 30 other Non-Small-Cell Lung Carcinoma trials with a reported enrollment target (30% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Small-Cell Lung Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Alectinib is the first listed.
NCT04351334 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT04351334 about?
NCT04351334 is a clinical study titled "Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC) Post-alectinib Treatment Patterns". This study aims to understand patient profiles, treatment patterns, and clinical outcomes among ALK-positive NSCLC patients treated with alectinib, and post-alectinib treatment patterns and outcomes.
What is the current status of trial NCT04351334?
This trial is currently completed. The enrollment target is 161 participants. The study started on 2020-03-01. Estimated completion is 2022-11-01.
What conditions does trial NCT04351334 study?
This clinical trial studies the following conditions: Non-Small-Cell Lung Carcinoma.
What interventions are being tested in trial NCT04351334?
The interventions under investigation include: Alectinib (DRUG).
Who is sponsoring clinical trial NCT04351334?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04351334 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small-Cell Lung Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors
RECRUITING
-
A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
RECRUITING · Phase 3
-
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Retifanlimab and Ruxolitinib In Solid Malignancies
RECRUITING · Phase 1
-
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.